Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm

LOS ANGELES, March 11, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Aardvark Therapeutics, Inc., ("Aardvark" or the "Company") (NASDAQ:AARD) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/aardvark-therapeutics-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

Aardvark’s stock price plummeted $7.02 per share, or 56.2%, to close at $5.47 per share on March 2, 2026, thereby injuring investors. This massive valuation collapse was triggered by a February 27, 2026, press release in which the Company announced it was "voluntarily pausing" its Phase 3 Hunger Elimination or Reduction Objective (HERO) trial. Management attributed the sudden suspension to "reversible cardiac observations" that were identified during routine safety monitoring in a healthy volunteer study. These issues were specifically noted at "above target therapeutic doses," leading the Company to halt both ongoing enrollment and dosing. Aardvark disclosed that it is currently "conducting a comprehensive review of the data" to determine the future of the HERO program, leaving the trial's timeline and the drug's regulatory prospects in significant doubt.

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.

Admitted CA, NY and TX Bar

lesley@portnoylaw.com

310-692-8883

www.portnoylaw.com

Attorney Advertising